Sun Pharma stock up 7.53 percent
Bangalore: Sun Pharma ended the trading as one of the top gainers with a gain of 
92.25 or 7.53 percent (Provisional). The stock of Sun Pharma opened the trading today at positive node and maintained the momentum throughout the day with trading in the range of 1,187.30 - 1,320. In all, 207.12 million shares were traded throughout the day with a current P/E at 18.33. The stock touched 52-week high of 1,600 and low of 953.
Sun Pharmaceutical Industries (Sun Pharma) is an international specialty pharmaceutical company. The company's product portfolio consists of four categories of products: India branded generics, U.S. generics, international branded generics and active pharmaceutical ingredients (API). The products of the company are prescribed in therapy areas like cardiology, psychiatry, neurology, gastroenterology, diabetology and respiratory. The company's subsidiaries include Sun Pharma Global, Sun Pharma Global-FZE, Sun Pharmaceutical (Bangladesh), Sun Pharmaceutical Peru S.A.C. and Sun Farmaceutica (Brazil). In November 2008, the company, along with its subsidiaries, completed the acquisition of Chattem Chemicals. In the quarter ended June 30, 2009, the company posted a net profit of 164 crore in compare to the corresponding quarter of previous year.
Other pharma companies have also traded in the green zone. Unichem Laboratories went up by 6.67 percent, Orchid Chemicals and Pharmaceuticals surged 9.19 percent, Glenmark Pharmaceuticals soars 3.58 percent and Lupin moved up 1.28 percent.
Out of 29 stock analysts currently following Sun Pharma, consensus recommendation is outperform, while seven recommended to buy, 11 recommended to hold and two asked to sell the stock. With 1,230,000 units of shares, 'HDFC Equity Fund' holds the highest number of shares in Sun Pharma.
92.25 or 7.53 percent (Provisional). The stock of Sun Pharma opened the trading today at positive node and maintained the momentum throughout the day with trading in the range of 1,187.30 - 1,320. In all, 207.12 million shares were traded throughout the day with a current P/E at 18.33. The stock touched 52-week high of 1,600 and low of 953.
Sun Pharmaceutical Industries (Sun Pharma) is an international specialty pharmaceutical company. The company's product portfolio consists of four categories of products: India branded generics, U.S. generics, international branded generics and active pharmaceutical ingredients (API). The products of the company are prescribed in therapy areas like cardiology, psychiatry, neurology, gastroenterology, diabetology and respiratory. The company's subsidiaries include Sun Pharma Global, Sun Pharma Global-FZE, Sun Pharmaceutical (Bangladesh), Sun Pharmaceutical Peru S.A.C. and Sun Farmaceutica (Brazil). In November 2008, the company, along with its subsidiaries, completed the acquisition of Chattem Chemicals. In the quarter ended June 30, 2009, the company posted a net profit of 164 crore in compare to the corresponding quarter of previous year.
Other pharma companies have also traded in the green zone. Unichem Laboratories went up by 6.67 percent, Orchid Chemicals and Pharmaceuticals surged 9.19 percent, Glenmark Pharmaceuticals soars 3.58 percent and Lupin moved up 1.28 percent.
Out of 29 stock analysts currently following Sun Pharma, consensus recommendation is outperform, while seven recommended to buy, 11 recommended to hold and two asked to sell the stock. With 1,230,000 units of shares, 'HDFC Equity Fund' holds the highest number of shares in Sun Pharma.